RxDoctor Payments DataLook up a doctor →

Laurence Radin, MD

Neurology · New London, CTNPI 1508860156

Payments from drug & device makers

$370,457in general payments, 2019–2025

Across 927 payments — averaging $399.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Adamas Pharmaceuticals, Inc.$218K
  • H. Lundbeck A S$49K
  • Amgen$42K
  • Avanir Pharmaceuticals, Inc.$24K
  • Eli Lilly$16K
  • Biohaven Pharmaceuticals, Inc.$8K
  • plus $13K from 54 others

What the payments were for

  • Speaking & faculty fees$2111%
  • Food & beverage$14,53398%
  • Education$700%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Adamas Pharmaceuticals, Inc.95$217,529
H. Lundbeck A S21$48,872
Amgen(2 entities)44$42,299
Avanir Pharmaceuticals, Inc.25$24,353
Eli Lilly3$16,303
Biohaven Pharmaceuticals, Inc.20$7,606
AbbVie(2 entities)69$1,279
Novartis52$1,099
Biogen45$1,072
EMD Serono, Inc.53$1,020
Neurocrine Biosciences, Inc.41$678
UCB, Inc.30$661
Teva Pharmaceuticals USA, Inc.39$629
Sunovion Pharmaceuticals Inc.32$573
Supernus Pharmaceuticals, Inc.37$543
Sanofi30$521
Eisai Inc.28$512
Lundbeck LLC22$451
SK Life Science, Inc.27$433
Pfizer19$368
Jazz Pharmaceuticals Inc.11$261
Biohaven Pharmaceutical Holding Company Ltd.12$245
Sumitomo Pharma America, Inc.10$222
Acorda Therapeutics, Inc13$211
Bristol Myers Squibb12$197
CSL Behring10$187
Johnson & Johnson10$177
Harmony Biosciences LLC6$175
Neurelis, Inc.8$165
Amneal Pharmaceuticals LLC8$160
Grifols USA, LLC11$158
Upsher-smith Laboratories LLC9$138
Lilly USA, LLC8$129
Assertio Therapeutics, Inc.10$118
Genentech USA, Inc.6$116
Kyowa Kirin, Inc.5$97
AstraZeneca(2 entities)4$75
Biodelivery Sciences International, Inc.5$73
TG Therapeutics, Inc.3$64
Greenwich Biosciences, Inc.3$48
Nevro Corp.1$46
Cala Health, Inc.1$40
Vertical Pharmaceuticals, LLC2$39
Mallinckrodt Enterprises LLC2$39
Avion Pharmaceuticals2$39
Acadia Pharmaceuticals Inc3$38
Aquestive Therapeutics, Inc.2$36
Impel Pharmaceuticals Inc.2$33
MDD US Operations, LLC1$28
Argenx US, Inc.1$27
Akcea Therapeutics, Inc.1$26
Scilex Pharmaceuticals Inc.1$25
Corium, LLC1$24
Abbott1$24
GE HealthCare1$22
Medtronic1$22
Shire North American Group Inc1$21
Mallinckrodt Hospital Products Inc.1$18
Promius Pharma LLC1$18
Strongbridge US Inc.1$17

How this compares

$370,457 in reported general payments places this provider in the 90th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Medicare billing

Part B allowed, 2024
$59,706
Medicare patients
214
Services billed
4,163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5012$135,747
Nurtec OdtRimegepant Sulfate33$59,001
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5012$57,044
OxycontinOxycodone Hcl24$21,521
NeuproRotigotine21$18,233
Gabapentin488$17,743
LamictalLamotrigine13$16,455
UbrelvyUbrogepant15$15,790
VimpatLacosamide12$13,009
Emgality PenGalcanezumab-Gnlm12$10,177
BotoxOnabotulinumtoxina12$9,089
Levetiracetam295$8,277
DilantinPhenytoin Sodium Extended17$6,788
Carbamazepine ErCarbamazepine57$6,772
Carbamazepine59$6,351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt, Dilantin$368$201,53562 claims
UCB, Inc.Neupro, Vimpat$661$31,24233 claims
AbbVieUbrelvy, Botox$1,279$24,87927 claims
Upsher-smith Laboratories LLCTopiramate$138$1,751108 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil$160$1,06122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 280 neurology providers in Connecticut.

Other neurology in New London

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →